KR20140069908A - Composition for promoting health of eyes - Google Patents
Composition for promoting health of eyes Download PDFInfo
- Publication number
- KR20140069908A KR20140069908A KR1020120137769A KR20120137769A KR20140069908A KR 20140069908 A KR20140069908 A KR 20140069908A KR 1020120137769 A KR1020120137769 A KR 1020120137769A KR 20120137769 A KR20120137769 A KR 20120137769A KR 20140069908 A KR20140069908 A KR 20140069908A
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- composition
- ginseng fruit
- extract
- chloride
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000036541 health Effects 0.000 title claims abstract description 26
- 230000001737 promoting effect Effects 0.000 title abstract description 4
- 235000008434 ginseng Nutrition 0.000 claims abstract description 93
- 241000208340 Araliaceae Species 0.000 claims abstract description 92
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 92
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 92
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 79
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 208000003464 asthenopia Diseases 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 14
- 229930182494 ginsenoside Natural products 0.000 claims description 13
- 235000010208 anthocyanin Nutrition 0.000 claims description 11
- 229930002877 anthocyanin Natural products 0.000 claims description 11
- 239000004410 anthocyanin Substances 0.000 claims description 11
- 150000004636 anthocyanins Chemical class 0.000 claims description 11
- 229940089161 ginsenoside Drugs 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- KQIKOUUKQBTQBE-UHFFFAOYSA-N 3,5,7-trihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KQIKOUUKQBTQBE-UHFFFAOYSA-N 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 claims description 4
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 claims description 2
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 claims description 2
- YTMNONATNXDQJF-QSLGVYCOSA-N cyanidin 3-O-beta-D-galactoside chloride Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-QSLGVYCOSA-N 0.000 claims description 2
- ADZHXBNWNZIHIX-XYGAWYNKSA-N cyanidin 3-O-rutinoside chloride Chemical compound [Cl-].O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O)=CC(O)=C3C=2)C=2C=C(O)C(O)=CC=2)O1 ADZHXBNWNZIHIX-XYGAWYNKSA-N 0.000 claims description 2
- 229960002067 keracyanin chloride Drugs 0.000 claims description 2
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 3
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 230000007407 health benefit Effects 0.000 abstract 1
- 230000007803 itching Effects 0.000 abstract 1
- 229940107131 ginseng root Drugs 0.000 description 14
- 238000009472 formulation Methods 0.000 description 11
- 206010016256 fatigue Diseases 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 210000000744 eyelid Anatomy 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- COAWNPJQKJEHPG-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 COAWNPJQKJEHPG-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 230000003217 anti-cancerogenic effect Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- 230000004313 glare Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- FIRXFHJQGIIJDB-UHFFFAOYSA-N 1-methyl-2,3-dihydroindole Chemical compound C1=CC=C2N(C)CCC2=C1 FIRXFHJQGIIJDB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- GPKJNSIFVWMEEI-UHFFFAOYSA-N 17-bromo-2,5,8,11,14-pentaoxabicyclo[13.4.0]nonadeca-1(15),16,18-triene Chemical compound O1CCOCCOCCOCCOC2=CC(Br)=CC=C21 GPKJNSIFVWMEEI-UHFFFAOYSA-N 0.000 description 1
- DIRROHKULXIUCB-DHJOXOLYSA-N 3,5-Bis(glucosyloxy)-4',7-dihydroxyflavylium chloride Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=CC(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DIRROHKULXIUCB-DHJOXOLYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- QDVZZZBBPRFPDG-DHJOXOLYSA-N Cyanin chloride Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=C(O)C(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QDVZZZBBPRFPDG-DHJOXOLYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 1
- 206010052128 Glare Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKWHWFONKJEUEF-WVXKDWSHSA-O Idaein Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 RKWHWFONKJEUEF-WVXKDWSHSA-O 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100225582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nip-1 gene Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 150000001915 cyanidin derivatives Chemical class 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000016732 phototransduction Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 238000004092 self-diagnosis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 명세서에 기재된 내용은 인체 건강에 대한 인삼 열매의 신규한 용도에 대한 것이다.Described herein is the novel use of ginseng fruit for human health.
인삼(Panax ginseng C.A. Meyer)은 오가피과 인삼속에 속하는 식물로 한국, 중국, 일본 등지에서 2,000여 년 전부터 사용되어 온 생약으로, 경험적으로 질병을 예방하고 수명을 연장시킬 목적으로 사용되어 왔으며, 지금까지 알려진 인삼의 효능 및 효과는 중추신경계에 대한 작용, 항발암 작용, 항암활성 작용, 면역기능 조절 작용, 항당뇨 작용, 간기능 항진효능, 심혈관 장해개선, 항동맥경화 작용, 혈압조절 작용, 갱년기 장애 개선, 골다공증에 미치는 효과, 항스트레스 작용, 항피로 작용, 항산화 활성, 노화억제 효능 등이 알려져 있다(최신고려인삼 "성분 및 효능편", 한국인삼연초연구원, 56-112, 1996).Ginseng (Panax ginseng CA Meyer) is a herb that has been used in Korea, China and Japan for over 2,000 years. It has been used for the purpose of preventing diseases and prolonging life span by empirical methods. The efficacy and effect of ginseng is improved by the action on the central nervous system, anti-carcinogenic action, anti-cancer activity action, immunity function control action, anti-diabetic action, liver function enhancement effect, cardiovascular disorder improvement, anti-arteriosclerosis action, blood pressure control action, , Antioxidant activity, antioxidant activity, antioxidant activity, and the like are known (Recent Ginseng "Ingredients and Efficacy", Korea Ginseng & Tobacco Research Institute, 56-112, 1996).
인삼의 대표적 생리활성 성분인 진세노사이드(Ginsenoside)는 인삼의 지상 및 지하부에 고르게 분포되어 있으며, 인삼근(뿌리), 인삼엽, 인삼 열매 등 부위에 따라 진세노사이드 함량뿐만 아니라 조성도 다른 것으로 알려져 있다(Attele AS et al, Biochem Pharmacol, 58; 1685-1693, 1999). Ginsenoside, which is a representative physiologically active ingredient of ginseng, is distributed evenly on the ground and underground of ginseng. Depending on the parts such as ginseng roots, ginseng leaves, and ginseng fruit, not only ginsenoside content but also composition is different (Attele AS et al, Biochem Pharmacol, 58: 1685-1693, 1999).
하지만 인삼열매에 함유된 구체적인 성분 및 눈 건강과 관련된 연구는 미흡한 실정이다.However, studies on specific ingredients and eye health in ginseng fruit are insufficient.
본 발명은 인체 건강에 대해 신규한 용도를 갖는 인삼 열매를 포함하는 조성물로서, 전반적인 눈건강 증진용 조성물을 제공하고자 한다. The present invention relates to a composition containing a ginseng fruit having a novel use for human health, and to provide a composition for promoting overall eye health.
상기한 목적을 달성하기 위하여, 본 발명의 일 실시예는 인삼 열매 추출물을 유효성분으로 함유하는 눈 건강 증진용 조성물을 제공한다.In order to achieve the above-mentioned object, an embodiment of the present invention provides a composition for improving eye health comprising an extract of ginseng fruit as an active ingredient.
또한, 본 발명의 일 실시예는 인삼 열매 추출물을 포함하는 눈의 피로도 개선용 조성물을 제공하는 것을 목적으로 한다.It is another object of the present invention to provide a composition for improving eye fatigue comprising ginseng fruit extract.
본 발명에 따른 조성물은 인삼 열매 추출물을 함유함으로써 눈 건강의 증진 효과가 우수하고, 눈의 피로도를 효과적으로 개선할 수 있다.The composition according to the present invention is excellent in improving the eye health by containing the ginseng fruit extract and can effectively improve the eye fatigue.
또한, 눈 건강 증진 효과 이외에도 피로감 개선, 정신적 안정감 제공, 피부 상태 개선, 손발 저림 개선, 갱년기 증상 완화 등 전반적으로 인체의 건강을 증진시켜줄 수 있다. In addition to improving eye health, it can improve the health of the human body as a whole by improving fatigue, providing mental stability, improving skin condition, improving limb comfort, and alleviating menopausal symptoms.
따라서, 본 발명에 따른 조성물은 식품 및 의약 분야에서 다양하게 활용가능하다.Accordingly, the composition according to the present invention can be used in various fields in food and medicine fields.
도 1은 본 발명의 일 실시예에 따른 인삼열매추출물과 비교예로 인삼근추출물의 진세노사이드 성분을 분석한 결과를 나타낸 그래프이다.
도 2는 본 발명의 일 실시예에 따른 인삼열매 추출물의 전반적인 눈 건강 개선도를 평가한 결과를 나타낸 그래프이다.1 is a graph showing the results of analysis of ginsenoside components of ginseng root extract according to an embodiment of the present invention and a comparative example thereof.
FIG. 2 is a graph showing the overall eye health improvement of ginseng fruit extract according to one embodiment of the present invention.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 일 실시예는 인삼열매 추출물을 유효성분으로 함유하는 눈 건강 증진용 조성물을 제공한다. One embodiment of the present invention provides a composition for enhancing eye health comprising an extract of ginseng fruit as an active ingredient.
인삼 열매는 인삼의 부위로서 통상적으로 사용되는 인삼근(뿌리)과는 함유된 성분의 종류 및 함량구성이 다르다. The ginseng fruit is a part of ginseng, and the type and content composition of ginseng root (root), which is commonly used, is different.
구체적으로, 인삼열매는 인삼근에 비해 비타민을 비롯한 미네랄 성분을 더 많이 함유한다. 또한, 인삼열매는 인삼근에 비해 진세노사이드를 더 많이 함유하며, 함유된 진세노사이드의 조성이 상이하다. 이에 본 발명의 일 실시예는 인삼열매 추출물이 진세노사이드 Re, Rg1, Rg2 등을 포함하는 진세노사이드 PT(Protopanaxatriol)계를 진세노사이드 Rb1, Rb2, Rc, Rd 등을 포함하는 진세노사이드 PD(Protopanaxadiol)계 보다 더 많이 함유할 수 있으며, 이에 따라 상이한 효과를 나타낼 수 있다. 예를 들어 인삼열매는 인삼근보다 우수한 항당뇨 효능을 나타내는 것으로 보고된바 있다(Dey L. et al., Phytomedicine, 10; 600-605, 2003).Specifically, the ginseng fruit contains more minerals such as vitamins than ginseng root. In addition, the ginseng fruit contains more ginsenoside than the ginseng root, and the composition of the ginsenoside contained is different. In one embodiment of the present invention, the ginseng fruit extract is a ginsenoside PT (Protopanaxatriol) system including ginsenosides Re, Rg1, Rg2, etc., with ginsenosides Rb1, Rb2, Rc, PD (Protopanaxadiol) system, and thus can exhibit different effects. For example, ginseng fruit has been reported to have superior antidiabetic efficacy than ginseng root (Dey L. et al., Phytomedicine, 10; 600-605, 2003).
또한, 인삼열매는 잎과 같은 녹색에서 과숙이 됨에 따라 품종에 따라 과육이 빨간색 또는 노란색으로 변하게 되는데, 이와 같이 과육의 색깔이 변함에 따라 인삼열매에는 안토시아닌(antocyanin)이 형성된다. 안토시아닌에는 예를 들어 시아닌 클로라이드(cyanidin chloride), 델피닌 클로라이드(delphinidin chloride), 말비딘 클로라이드(malvidin chloride), 페라고닌 클로라이드(pelargonin chloride), 시아닌 클로라이드(cyanin chloride), 아이디어인 클로라이드(ideain chloride), 케라시아닌 클로라이드(keracyanin chloride), 쿠로마닌 클로라이드(kuromanin chloride), 페라고니딘 클로라이드(pelagonidin chloride), 페튜니딘 클로라이드(petunidin chloride) 등이 있다(Nat. Prod. REP., 2009, 26, 1001-1043). 그리고 안토시아닌은 항산화, 항알러지, 항염증, 항 바이러스, 항증식성, 항 돌연변이, 항균, 항발암성, 심혈관 손상 및 알러지로부터의 보호, 미소순환 보호, 말초 모세혈관 저항 보호, 당뇨병 개선 등에 효과가 있는 것으로 보고되고 있다(Asia Pac J Clin Nutr. 2007;16(2):200-8).In addition, the fruit of the ginseng becomes greenish in the green like leaf, and the flesh turns into red or yellow depending on the kind. As the color of the flesh changes, anthocyanin is formed in the ginseng fruit. Anthocyanins include, for example, cyanidin chloride, delphinidin chloride, malvidin chloride, pelargonin chloride, cyanin chloride, ideine chloride, Keracyanin chloride, kuromanin chloride, pelagonidin chloride, petunidin chloride, etc. (Nat. Prod. REP., 2009, 26,1001-1043). And anthocyanins are effective for antioxidant, antiallergic, anti-inflammatory, antiviral, antiproliferative, antimutagenic, antimicrobial, anticarcinogenic, cardiovascular and allergic protection, microcirculation protection, peripheral capillary resistance protection, (Asia Pac J Clin Nutr 2007; 16 (2): 200-8).
따라서, 본 발명의 일 실시예에 따른 조성물은 인삼열매 추출물이 상기와 같이 풍부한 비타민, 미네랄, 진세노사이드, 안토시아닌 등을 함유할 수 있으므로, 눈의 피로감, 건조감 등을 개선함으로써 눈의 건강을 전반적으로 증진시켜줄 수 있다.Accordingly, the composition according to one embodiment of the present invention can contain vitamins, minerals, ginsenosides, anthocyanins and the like as described above, so that the ginseng fruit extract can improve the eye health, .
안토시아닌은 눈의 망막에 있는 막대모양의 간상세포에 함유되어 있는 붉은색의 빛을 감지하는 단백질인 로돕신(rhodopsin)과 결합할 수 있고, 포스포디에스테라아제(phosphodiesterase, PDE)의 광전환(phototransduction)과정에 영향을 미칠 수 있으므로, 야간 시력을 증진시켜주고 눈건강을 개선시켜줄 수 있다(Asia Pac J Clin Nutr 2007;16 (2):200-208).
Anthocyanin can bind to rhodopsin, a protein that senses red light contained in rod-like cells in the retina of the eye, and can be used in phototransduction processes of phosphodiesterase (PDE) , Which can improve night vision and improve eye health (Asia Pac J Clin Nutr 2007; 16 (2): 200-208).
또한, 본 발명의 일 실시예에 따른 인삼 열매 추출물은In addition, according to one embodiment of the present invention,
(a)인삼열매를 전처리 하는 단계;및(a) pretreating the fruit of ginseng; and
(b)상기 단계에서 전처리한 인삼열매를 물 또는 유기용매로 추출하여 인삼 열매 추출물을 얻는 단계;에 의해 제조될 수 있다.(b) extracting the ginseng fruit pretreated in the above step with water or an organic solvent to obtain a ginseng fruit extract.
상기 (a)단계에서 인삼열매는 생인삼열매일 수 있으며, 인삼열매의 과육과 과피는 일광건조 또는 열풍 건조를 통하여 건조될 수 있다.In step (a), the ginseng fruit may be three-diarrhea per day, and the flesh and skin of the ginseng fruit may be dried through daylight drying or hot air drying.
또한, 상기 (b)단계에서 인삼열매 추출물은 건조된 인삼 열매를 물 또는 유기용매를 사용하여 상온에서 환류 추출한 후, 감압농축하여 제조될 수 있다.
In step (b), the ginseng fruit extract may be prepared by extracting dried ginseng fruit with water or an organic solvent under reflux at room temperature, and then concentrating the extract under reduced pressure.
본 발명의 일 실시예에 따른 조성물은 조성물의 형태에 따라 인삼 열매 추출물을 조성물 총 중량에 대하여 0.01~100중량%로 함유할 수 있다.The composition according to an embodiment of the present invention may contain 0.01 to 100% by weight of ginseng fruit extract, based on the total weight of the composition, depending on the form of the composition.
또한, 본 발명의 다른 일 실시예에 따른 조성물은 정제, 환제, 단제, 캡슐제, 과립제, 산제, 연고제, 드링크제 또는 주사제 등의 형태로 약학 조성물 또는 식품 조성물로서 제형화할 수 있다.In addition, the composition according to another embodiment of the present invention may be formulated as a pharmaceutical composition or a food composition in the form of tablets, pills, tablets, capsules, granules, powders, ointments, drinks or injections.
본 발명은 일 실시예로서 통상적인 방법에 따라 인삼 열매 추출물을 함유하는 약학 조성물을 제공한다. 약학 제형의 제조에 있어서, 활성 성분을 담체와 함께 혼합 또는 희석하거나, 용기 형태의 담체 내에 봉입시키는 것이 바람직하다. 담체가 희석제로 사용되는 경우에는 활성 성분에 대한 담체, 부형제 또는 매질(medium)로 작용하는 고형, 반고형 또는 액상의 물질일 수 있다. 따라서, 제형은 정제, 환제, 분제, 사쉐, 엘릭시르, 현탁제, 유제, 용액제, 시럽제, 에어로졸, 연질 또는 경질 젤라틴 캅셀제, 멸균 주사제, 멸균 분제 등의 형태일 수 있다.The present invention provides, as an embodiment, a pharmaceutical composition containing a ginseng fruit extract according to a conventional method. In the manufacture of pharmaceutical formulations, it is preferred that the active ingredient is mixed with or diluted with the carrier, or enclosed within a carrier in the form of a container. When the carrier is used as a diluent, it may be a solid, semi-solid or liquid substance acting as a carrier, excipient or medium for the active ingredient. Thus, the formulations may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injections, sterile powders and the like.
적합한 담체, 부형제 및 희석제의 예로는, 락토로스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제형은 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 포함할 수 있다. 본 발명의 조성물은 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 사용하여 제형화될 수 있다.Examples of suitable carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, Hydroxybenzoate, talc, magnesium stearate, and mineral oil. The formulations may additionally include fillers, anti-coagulants, lubricants, wetting agents, perfumes, emulsifiers, preservatives, and the like. The compositions of the present invention may be formulated using methods well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal.
본 발명의 약학 조성물은 경구, 경피, 피하, 정맥, 복강, 근육, 국소도포, 첩포 및 이온토포레시스(iontophoresis)를 포함한 여러 경로를 통해 투여될 수 있고, 이 중에서 국소 적용 및 경구투여가 바람직하다.The pharmaceutical composition of the present invention may be administered through various routes including oral, transdermal, subcutaneous, intravenous, intraperitoneal, muscle, topical application, patch and iontophoresis, and local application and oral administration are preferred Do.
사람의 경우, 활성 화합물의 통상적인 1일 투여량은 1 내지 100mg/kg체중, 바람직하게는 5 내지 70mg/kg체중의 범위일 수 있고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 활성 성분의 실제 투여량은 치료할 질환, 투여 경로, 환자의 연령, 성별 및 체중, 및 질환의 중증도 등의 여러 관련 인자에 비추어 결정되어야 하는 것으로 이해되어야 하며, 따라서, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.In the case of humans, the usual daily dose of the active compound may range from 1 to 100 mg / kg body weight, preferably from 5 to 70 mg / kg body weight, and may be administered in single or divided doses. It should be understood, however, that the actual dosage of the active ingredient should be determined in light of various relevant factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, and the severity of the disease, Are not intended to limit the scope of the invention.
또한, 본 발명은 일 실시예로서 통상적인 방법에 따라 인삼 열매 추출물을 함유하는 식품 조성물을 제공한다.In addition, the present invention provides, as an embodiment, a food composition containing a ginseng fruit extract according to a conventional method.
본 발명의 식품 조성물은 액상 또는 고체 상태의 제형을 갖는데 제형이 특별히 한정되지 않으며, 예를 들어, 정제, 과립제, 드링크제, 캬라멜, 다이어 트바 등으로 제형화될 수 있다. 각 제형의 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.
The food composition of the present invention has a liquid or solid form, and the formulation is not particularly limited. For example, it may be formulated into tablets, granules, drinks, caramels, diabas, and the like. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients.
이하, 본 발명을 하기의 실시예 및 시험예를 통하여 설명한다. 실시예 및 시험예는 본 발명을 보다 상세히 설명하기 위한 것으로 본 발명의 범위가 하기의 실시예의 범위로 제한되는 것은 아니다. Hereinafter, the present invention will be described with reference to the following examples and test examples. The examples and the test examples are for illustrating the present invention in more detail, and the scope of the present invention is not limited to the range of the following examples.
또한, 이 기술분야의 통상의 지식을 가진 자이면 누구나 이 발명의 기술 사상의 범주를 이탈하지 않고 첨부한 특허청구범위 내에서 다양한 변형 및 모방이 가능함은 명백한 사실이다.
It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope of the invention.
[실시예 1] 인삼 열매 추출물 제조[Example 1] Preparation of ginseng fruit extract
인삼 열매 전처리Ginseng fruit pretreatment
생(生)인삼 열매를 수확하여 종자를 분리하여 제거한 후 인삼 열매의 과육과 과피를 일광건조 또는 열풍건조를 통하여 인삼 열매 건조원료를 제조하였다.The raw ginseng fruit was harvested and the seeds were separated and removed. Then, the ginseng fruit and the skin of the ginseng fruit were dried with sunshine or hot air to prepare dry ingredients of ginseng fruit.
인삼 열매 추출물 제조Manufacture of ginseng fruit extract
인삼 열매 건조물 1kg에 물 또는 주정(에탄올) 3L를 가하여 상온에서 환류 추출한 다음, 여과한 후 40~45℃에서 감압농축하여 인삼 열매 추출물 300g을 얻었다.
3 kg of water or alcohol (ethanol) was added to 1 kg of dried ginseng fruit, and the mixture was refluxed at room temperature, filtered and concentrated under reduced pressure at 40 to 45 ° C to obtain 300 g of ginseng fruit extract.
[비교예 1] 인삼근 추출물 제조[Comparative Example 1] Production of ginseng muscle root extract
상기 실시예 1에서 인삼 열매 대신에 인삼근(뿌리)을 사용한 것을 제외하고 실시예 1과 동일한 방법으로 제조하였다.
Example 1 was prepared in the same manner as in Example 1, except that ginseng root (root) was used instead of ginseng fruit.
[시험예 1] 인삼 열매 추출물의 성분 비교[Test Example 1] Comparison of components of ginseng fruit extract
<인삼 열매와 인삼근의 진세노이드(인삼사포닌) 성분 분석><Analysis of Ginseng Saponin Components of Ginseng Fruit and Ginseng Root>
본 발명의 일 실시예에 따른 실시예 1의 인삼 열매와 비교예 1의 인삼근 추출물을 각각 제조한 다음, 이들 추출물에 에테르(ether)를 처리하여 지용성 성분을 제거한 후 부탄올(BuOH)로 조사포닌을 추출, 농축하여 HPLC를 통한 진세노이드 성분 분석을 실시하였으며, 그 결과를 도 1 및 하기 표 1에 나타내었다.The ginseng fruit of Example 1 and the ginseng muscle extract of Comparative Example 1 according to one embodiment of the present invention were each prepared, and then the ether was treated to remove the fat-soluble components and then the crude saponin Was extracted and concentrated to analyze the ginsenoside components via HPLC. The results are shown in FIG. 1 and Table 1 below.
분석결과, 도 1 및 표 1에 나타난 바와 같이 실시예 1에서 제조한 인삼 열매 추출물은 조사포닌 함량에 있어서 비교예 1에서 제조한 인삼근 추출물보다 약 2배 이상의 함량을 가지고 있는 것으로 나타났다. As a result of the analysis, as shown in FIG. 1 and Table 1, the ginseng fruit extract prepared in Example 1 had about twice the crude saponin content than the ginseng root extract prepared in Comparative Example 1.
함량비에 있어서는 진세노사이드를 PD(Protopanaxadiol)계-진세노사이드 Rb1, Rb2, Rc 및 Rd 및 PT(Protopanaxatriol)계-진세노사이드 Re, Rg1 및 Rg2의 비율로 구분하였을 때 각각 0.73과 3.23으로 분석되어, 인삼 열매와 인삼근에 함유된 진세노사이드의 조성 및 함량은 상반된 특징을 나타냄을 알 수 있었다. 또한, 인삼 열매 추출물은 이 중에서도 진세노사이드 Re를 인삼근 추출물보다 약 9배 정도 특히 더 많이 함유하고 있는 것으로 나타났다.
The content ratio of ginsenosides was 0.73 and 3.23, respectively, when the ratio of protopanaxadiol-ginsenosides Rb1, Rb2, Rc and Rd and PT (Protopanaxatriol) -ginsenoside Re, Rg1 and Rg2 was The composition and contents of ginsenosides contained in the ginseng fruit and ginseng root showed opposite characteristics. In addition, the ginseng fruit extract contained about 9 times more ginsenoside Re than Ginseng root extract.
<인삼 열매 추출물의 미네랄 성분 분석><Mineral composition analysis of ginseng fruit extract>
실시예 1에서 제조한 인삼 열매 추출물이 인삼과는 다른 "과실"로서의 특징을 가짐을 구분하기 위하여 비타민을 비롯한 미네랄 성분의 분석을 실시하였으며, 그 결과를 하기 표 2에 나타내었다. The ginseng fruit extract prepared in Example 1 was analyzed for minerals including vitamins in order to distinguish it from "ginseng" which is different from ginseng. The results are shown in Table 2 below.
상기 표 2의 결과와 같이 본 발명의 일 실시예에 따른 인삼 열매는 인삼근과 달리 전반적으로 비타민과 미네랄 16종의 함량이 매우 풍부하였다.
As shown in Table 2, the ginseng fruit according to one embodiment of the present invention is rich in 16 kinds of vitamins and minerals in general, unlike the ginseng root.
이와 같이, 본 발명의 일 실시예에 따른 인삼 열매는 성분적으로 인삼근보다 많은 인삼사포닌을 함유함과 동시에 사포닌 조성의 성질이 정반대이고, 또한 인삼근과 달리 열매로서 비타민과 미네랄 16종의 함량이 풍부함을 확인할 수 있었다.
As described above, the ginseng fruit according to one embodiment of the present invention contains more ginseng saponin than the ginseng root and has the opposite properties of the saponin composition. Also, unlike the ginseng root, the content of 16 kinds of vitamins and minerals I could confirm this richness.
<인삼 열매 추출물의 안토시아닌 성분 분석><Analysis of anthocyanin components of ginseng fruit extract>
본 발명의 일 실시예에 따라 제조한 실시예 1의 인삼 열매 추출물에 함유된 안토시아닌 성분을 정량분석하였다.Anthocyanin components contained in the ginseng fruit extract of Example 1 prepared according to one embodiment of the present invention were quantitatively analyzed.
이때, 안토시아니딘 키트(시아니딘 클로라이드, 델피니딘 클로라이드, 말비딘 클로라이드, 페라고닌 클로라이드), 시아니딘 유도체 키트(시아니딘 클로라이드, 시아닌 클로라이드, 아이디어인 클로라이드, 케라시아닌 클로라이드, 쿠로마닌 클로라이드), 페라고니딘 클로라이드, 페튜니딘 클로라이드 표준을 이용하여 인삼열매 안토시아닌을 정량분석하였고, 그 결과를 표 3에 나타내었다.At this time, an anthocyanidin kit (cyanidin chloride, delpidine hydrochloride, malbidin chloride, pelarone chloride), cyanidin derivative kit (cyanidin chloride, cyanine chloride, ideine chloride, ), Ferragonidine chloride, and fetudinidine chloride standards. The results are shown in Table 3. The results are shown in Table 3.
분석결과 상기 표 3에 나타난 바와 같이, 말비딘 클로라이드, 아이디어인 클로라이드, 페라고닌 클로라이드, 케라시아닌 클로라이드의 양이 각각 12.17, 2.36, 8.28, 3.29 ppm으로 정량되었고, 네 성분의 합은 총 26.1 ppm으로 측정되어, 안토시아닌이 풍부하게 함유되어 있음을 알 수 있었다.
As shown in Table 3, the amounts of malvidin chloride, ide phosphoryl chloride, ferulenin chloride and kerocyanine chloride were determined to be 12.17, 2.36, 8.28 and 3.29 ppm, respectively, and the sum of the four components was 26.1 ppm, indicating that anthocyanin was abundantly contained.
[시험예 2] 눈건강 개선도 평가 [Test Example 2] Evaluation of eye health improvement
상기 시험예 1의 결과를 바탕으로, 본 발명의 일 실시예에 따라 인삼 열매 추출물을 함유하는 조성물을 인체에 직접 사용한 경우에 나타나는 눈 건강 지표의 변화를 관찰 및 평가하였다. 즉, 인삼 열매 추출물의 섭취 전후에 있어서 눈건강상의 변화를 다음의 방법으로 평가하였다. Based on the results of Test Example 1, the change of the eye health index when the composition containing the ginseng fruit extract was directly applied to the human body was observed and evaluated according to one embodiment of the present invention. In other words, changes in eye health before and after consumption of ginseng fruit extract were evaluated by the following methods.
실험을 위하여 실시예 1의 인삼열매 추출물을 100중량%로 함유하는700mg의 정제를 제조하였다. 이때 table top 단발타정기(ERWEKA.독일)를 이용하여 타정하였다.For the experiment, 700 mg tablets containing 100% by weight of the ginseng fruit extract of Example 1 were prepared. At this time, the tablet was tableted using a single-handed tableting machine (ERWEKA, Germany).
그리고 10~50대 남녀를 58명을 대상으로 하여 상기 인삼 열매 추출물을 함유하는 정제를 4주 동안 1일 2회, 1회 2정씩 섭취하게 하였다. 즉, 표준화시킨 인삼열매추출물을 1일 1400mg씩 섭취하게 하였다.Then, the tablets containing the above ginseng fruit extract were administered to 58 persons in 10 to 50 years old men and women for 2 weeks, twice a day for 4 weeks. That is, standardized ginseng fruit extract was taken at 1400 mg per day.
이와 동시에, 아래와 같은 방법으로 대하여 섭취 전 및 후에 전반적인 눈건강 지표에 대한 설문 조사를 하였다. At the same time, we surveyed the overall eye health index before and after ingestion by the following method.
평소에 느끼는 눈 관련 불편 증상 19가지로서 피로감, 압박감, 안검(눈꺼풀) 피로, 눈물 흐름, 열감, 건조감, 통증, 간지러움, 안검(눈꺼풀) 경련, 잔상, 눈부심, 눈시림, 충혈, 침침함, 이물감, 눈꼽, 오후 시간대 피로감, 작열감 및 초점조절시간의 각 증상에 대한 불편 정도(1-15점)를 체크하게 하였다. 매우 불편한 경우를 15점, 불편함이 전혀 느껴지지 않은 경우를 1점으로 하여 체크하게 하였다. 평가 결과는 인삼 열매 추출물의 섭취 전 후 눈건강 자가진단 점수의 변화로 하기 표 4 및 도 2에 나타내었다(N=58).There are 19 symptoms of eye related discomfort that I usually feel as tiredness, pressure, eyelid fatigue, tear flow, fever, dry feeling, pain, tickling, eyelid convulsion, afterimage, glare, (1-15 points) for each symptom of fatigue, burning sensation, and focus adjustment time. 15 points for very uncomfortable, and 1 point for no discomfort. The results are shown in Table 4 and Figure 2 (N = 58) as a change in the eye health self-diagnosis score before and after ingestion of the ginseng fruit extract.
평균±S.DBefore ingestion
Mean ± SD
평균±S.DAfter ingestion
Mean ± SD
상기 표 4 및 도 2에 나타난 바와 같이, 피험자들은 인삼 열매 추출물을 섭취한 후 눈의 피로감을 비롯하여 전반적으로 눈의 건강상태가 50%이상 증진된 것으로 평가하여, 인삼 열매 추출물이 눈 건강 증진에 매우 효과적임을 알 수 있었다.As shown in Table 4 and FIG. 2, the subjects were evaluated that the health condition of the eyes including the fatigue of the eyes after the ingestion of the fruit extract of the ginseng was improved by 50% or more and the extract of the ginseng fruit It was found to be effective.
또한, 상기한 시험예 2의 결과에 더하여 피험자들은 인삼 열매 추출물을 섭취 후 눈 뿐만 아니라 전체적인 신체의 피로감이 개선되고 정신적인 안정감을 느낄 수 있었으며, 피부 상태가 개선되고 손발 저림이 없어졌으며 갱년기 증상이 완화되었다고 기록하였다. 따라서, 이를 통하여 인삼 열매 추출물은 눈을 비롯하여 전반적으로 인체의 건강 증진에 매우 효과적임을 알 수 있었다.
In addition, in addition to the results of Test Example 2, the subjects were able to feel an improvement in overall body fatigue and mental stability as well as eyes after intake of ginseng fruit extract, improved skin condition, As well. Therefore, it was found that the extract of Ginseng fruit is very effective for promoting the health of the human body including eyes.
본 발명의 일 실시예에 따른 조성물의 제형예를 아래에서 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.
Formulation examples of compositions according to one embodiment of the present invention are described below, but may be applied to various other formulations, which are not intended to be limiting but merely illustrative of the invention.
[제형예 1] 인삼열매 100% 엑기스[Formulation Example 1] 100% extract of ginseng fruit
실시예 1의 인삼 열매 추출물 제조 시 고형분 60% 이상이 되도록 농축하여, 저온에서 숙성한 후 액상형태의 100% 엑기스 제품을 제조하였다.
The ginseng fruit extract of Example 1 was concentrated to a solid content of at least 60%, and after aging at a low temperature, a liquid form of 100% extract was prepared.
[제형예 2] 연질캅셀제[Formulation Example 2] Soft capsule
실시예 1의 인삼 열매 추출물 110mg, 팜유 0.8mg, 식물성 경화유 0.48mg, 황납 2.4mg 및 레시틴 3.6mg을 혼합하고, 통상의 방법에 따라 충진하여 연질 캅셀을 제조하였다.
A soft capsule was prepared by mixing 110 mg of the ginseng fruit extract of Example 1, 0.8 mg of palm oil, 0.48 mg of vegetable hardened oil, 2.4 mg of yellowing powder and 3.6 mg of lecithin and filling them according to a conventional method.
[제형예 3] 정제[Formulation Example 3] Tablets
실시예 1의 인삼 열매 추출물 160mg, 포도당 200㎎ 및 덱스트린 196㎎을 혼합하고 유동층 건조기를 이용하여 과립한 후 당 에스테르(sugar ester) 7 mg을 첨가하여 타정기로 타정하여 정제를 제조하였다.
160 mg of the ginseng fruit extract of Example 1, 200 mg of glucose, and 196 mg of dextrin were mixed and granulated using a fluidized bed drier, and then 7 mg of sugar ester was added thereto and tableted by tabletting.
[제형예 4] 환의 제조[Formulation Example 4] Production of pills
실시예 1의 인삼 열매 추출물 0.9g, 당 0.3g, 전분 1.91g 및 글리세린 0.56g을 혼합하고, 제환기를 사용하여 환을 제조하였다.
0.9 g of the ginseng fruit extract of Example 1, 0.3 g of sugar, 1.91 g of starch and 0.56 g of glycerin were mixed and a ring was prepared using a ventilator.
[제조예 5] 과립제[Preparation Example 5]
실시예 1의 인삼 열매 추출물 160mg, 포도당 200㎎ 및 덱스트린 196㎎을 혼합하고 유동층 건조기를 이용하여 과립한 후, 포에 충진하여 과립제를 제조하였다.
160 mg of the ginseng fruit extract of Example 1, 200 mg of glucose and 196 mg of dextrin were mixed, granulated using a fluidized bed drier, and filled in a bag to prepare a granule.
[제조예 6] 드링크제[Production Example 6]
실시예 1의 인삼 열매 추출물 110mg, 포도당 10g 및 구연산 2g을 혼합한 후 정제수 188g을 가하여 각 병에 200㎖씩 충진되도록 하였다. 병에 충진한 다음 90℃에서 2∼3시간 살균하여 음료를 제조하였다.
110 mg of the ginseng fruit extract of Example 1, 10 g of glucose, and 2 g of citric acid were mixed and then 188 g of purified water was added to fill each bottle with 200 ml each. The beverage was filled in bottles and sterilized at 90 ° C for 2-3 hours.
Claims (7)
(a)인삼열매를 전처리 하는 단계;및
(b)상기 단계에서 전처리한 인삼열매를 물 또는 유기용매로 추출하여 인삼 열매 추출물을 얻는 단계;를 포함하는 방법으로 제조하는 것을 특징으로 하는 눈 건강 증진용 조성물.The method according to claim 1, wherein the ginseng fruit extract
(a) pretreating the fruit of ginseng; and
(b) extracting the ginseng fruit pretreated in the above step with water or an organic solvent to obtain a ginseng fruit extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120137769A KR102011451B1 (en) | 2012-11-30 | 2012-11-30 | Composition for promoting health of eyes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120137769A KR102011451B1 (en) | 2012-11-30 | 2012-11-30 | Composition for promoting health of eyes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140069908A true KR20140069908A (en) | 2014-06-10 |
KR102011451B1 KR102011451B1 (en) | 2019-08-16 |
Family
ID=51124922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120137769A KR102011451B1 (en) | 2012-11-30 | 2012-11-30 | Composition for promoting health of eyes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102011451B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016129902A1 (en) * | 2015-02-13 | 2016-08-18 | (주)아모레퍼시픽 | Composition for preventing, alleviating or treating burnout syndrome |
KR20230032526A (en) | 2021-08-31 | 2023-03-07 | (주)아모레퍼시픽 | Composition for inhibiting eye damage |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080094540A (en) | 2007-04-20 | 2008-10-23 | (주)아모레퍼시픽 | Composition of skin external application containing ginseng fruit extracts |
WO2012157790A1 (en) * | 2011-05-13 | 2012-11-22 | (주)아모레퍼시픽 | Composition containing ginseng berry extract for activating mitochondria |
-
2012
- 2012-11-30 KR KR1020120137769A patent/KR102011451B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080094540A (en) | 2007-04-20 | 2008-10-23 | (주)아모레퍼시픽 | Composition of skin external application containing ginseng fruit extracts |
WO2012157790A1 (en) * | 2011-05-13 | 2012-11-22 | (주)아모레퍼시픽 | Composition containing ginseng berry extract for activating mitochondria |
Non-Patent Citations (4)
Title |
---|
Asia Pac J Clin Nutr. 2007;16(2):200-208 |
Attele AS et al, Biochem Pharmacol, 58; 1685-1693, 1999 |
Dey L. et al., Phytomedicine, 10; 600-605, 2003 |
Nat. Prod. REP., 2009, 26, 1001-1043 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016129902A1 (en) * | 2015-02-13 | 2016-08-18 | (주)아모레퍼시픽 | Composition for preventing, alleviating or treating burnout syndrome |
KR20160099972A (en) * | 2015-02-13 | 2016-08-23 | (주)아모레퍼시픽 | Composition for preventing, improving or treating burn out syndrome |
CN107223056A (en) * | 2015-02-13 | 2017-09-29 | 株式会社爱茉莉太平洋 | Composition for preventing, alleviating or treating fatigue syndrome |
TWI708609B (en) * | 2015-02-13 | 2020-11-01 | 南韓商愛茉莉太平洋股份有限公司 | Composition for preventing, improving or treating burn out syndrome |
US11975037B2 (en) | 2015-02-13 | 2024-05-07 | Amorepacific Corporation | Composition for preventing, alleviating or treating burnout syndrome |
KR20230032526A (en) | 2021-08-31 | 2023-03-07 | (주)아모레퍼시픽 | Composition for inhibiting eye damage |
Also Published As
Publication number | Publication date |
---|---|
KR102011451B1 (en) | 2019-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10842805B2 (en) | Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses | |
Kumari et al. | Rauvolfia serpentina L. Benth. ex Kurz.: phytochemical, pharmacological and therapeutic aspects | |
US10172900B2 (en) | Composition with improved bioavailabilty of saponin and method for improving the bioavailability of saponin | |
JP6031662B2 (en) | Cognitive decline improvement composition | |
Khan et al. | Chamomile tea: herbal hypoglycemic alternative for conventional medicine. | |
KR20150005430A (en) | Composition for relieving premenstrual syndrome and menstrual pain | |
MXPA06007498A (en) | Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent for the treatment of chronic venous insufficiences. | |
TWI708609B (en) | Composition for preventing, improving or treating burn out syndrome | |
KR20140069908A (en) | Composition for promoting health of eyes | |
MXPA06007497A (en) | Composition comprising an aqueous extract of red vine leaves and a antithrombotic agent for the treatment of chronic venous insufficiences. | |
KR100569089B1 (en) | Composition having brain function and congnition enhancing activity | |
KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
KR100638344B1 (en) | Composition comprising the crude drug extract for improving eye symptoms of VDT syndrome | |
KR101600745B1 (en) | A pharmaceutical composition comprising the complex extract of herb medicine | |
KR102395338B1 (en) | Oral composition for improving systemic symptoms including sensitivity to cold | |
KR102617383B1 (en) | Anti-obesity composition using pomegranate, dioscorea rhizoma and polygonatum odratum extract as effective component and manufacturing method thereof | |
KR101596006B1 (en) | Composition for Prevention and Treatment of Cardiovascular Diseases | |
KR100555653B1 (en) | Composition comprising an extract of processed Panax genus plant for preventing and treating anxiety | |
KR101307726B1 (en) | A composition comprising the extract of Angelica dahurica for preventing and treating drug intoxication or withdrawal symptoms | |
KR102441302B1 (en) | Composition for anti-cancer containing deacetyl torilin as effective component | |
KR20150042769A (en) | A pharmaceutical composition comprising the complex extract of herb medicine | |
Hasan et al. | The incredible health benefits of saffron: A Review | |
KR20220103326A (en) | Composition for improvement, prevention or treatment of depression comprising herbal medicine mixture as effective component | |
KR20150015823A (en) | A pharmaceutical composition comprising the complex extract of herb medicine | |
KR101649475B1 (en) | Pharmaceutical composition for the prevention or treatment of brain disease and food composition for the protection of brain with ergosterol peroxide or the extract of Reynoutria sachalinensis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E90F | Notification of reason for final refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) |